Medical therapy in venous thromboembolism

Area of Science:

• Cardiology
• Hematology
• Vascular Medicine

Background:

• Standard treatment for deep vein thrombosis (DVT) and pulmonary embolism (PE) involves parenteral anticoagulants followed by vitamin K antagonists.
• Emerging oral anticoagulants show potential to replace current treatment regimens, including initial parenteral therapy.

Purpose of the Study:

• To review current and future anticoagulation strategies for DVT and PE.
• To discuss the optimal duration of anticoagulation and risk stratification for recurrence.

Main Methods:

• Review of existing literature on anticoagulation therapies for DVT and PE.
• Analysis of clinical risk factors and laboratory markers (e.g., D-dimer) for predicting recurrence.

Main Results:

• Anticoagulation for at least 3 months is crucial to prevent recurrence.
• Prolonged therapy may be beneficial for patients with specific risk factors.
• D-dimer and combined clinical/laboratory models show promise in risk stratification, pending validation.

Conclusions:

• New oral anticoagulants may offer future alternatives to current standards of care.
• Individualized anticoagulation duration based on risk assessment is essential for managing DVT and PE.
• Further validation of predictive models is needed for routine clinical application.